Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo

British Journal of Pharmacology

Volumn 168, Issue 6, 2013, Pages 1316-1328

  Ford, S J ^a   Obeidy, P ^b   Lovejoy, D B ^b   Bedford, M ^a   Nichols, L ^a   Chadwick, C ^a   Tucker, O ^a   Lui, G Y L ^b   Kalinowski, D S ^b   Jansson, P J ^b   Iqbal, T H ^a   Alderson, D ^a   Richardson, Des R ^b   Tselepis, Chris ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

cancer; deferasirox; iron chelation; oesophageal cancer

Indexed keywords

CD71 ANTIGEN; CISPLATIN; DEFERASIROX; DEFEROXAMINE; EPIRUBICIN; FLUOROURACIL; IRON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL LEVEL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ESOPHAGUS CANCER; ESOPHAGUS TUMOR; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; IRON METABOLISM; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOATES; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DEFEROXAMINE; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; MICE; MICE, INBRED BALB C; MICE, NUDE; TRIAZOLES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874405929     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12045     Document Type: Review

References (54)

1. Boult J, Roberts K, Brookes MJ, Hughes S, Bury JP, Cross SS, et al. (2008). Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin Cancer Res 14: 379-387.
2. Brookes MJ, Boult J, Roberts K, Cooper BT, Hotchins NA, Matthews G, et al. (2008). A role for iron in Wnt signalling. Oncogene 27: 966-975.
3. Cancer Research UK (CRUK) (2012). Oesophageal cancer statistics. Available at: http://info.cancerresearchuk.org/cancerstats/types/oesophagus/ (accessed 1 March 2012).
4. Cappellini MD, (2008). Long-term efficacy and safety of deferasirox. Blood Rev 22: 35-41.
5. Chantrel-Groussard K, Gaboriau F, Pasdeloup N, Havouis R, Nick H, Pierre JL, et al. (2006). The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox. Eur J Pharmacol 541: 129-137.
6. Chen X, Yang G, Ding WY, Bondoc F, Curtis SK, Yang CS, (1999). An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload. Carcinogenesis 20: 1801-1808.
7. Chen X, Ding WY, Yang G, Bondoc F, Lee MJ, Yang CS, (2000). Oxidative damage in an esophageal adenocarcinoma model with rats. Carcinogenesis 21: 257-263.
8. Courrech Staal EF, Aleman BM, Boot H, van, Velthuysen ML, van, Tinteren H, van, Sandick JW, (2010). Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg 97: 1482-1496.
9. Daniels TR, Bernabeu E, Rodriguez JA, Patel S, Kozman M, Chiappetta DA, et al. (2012). The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 1820: 291-317.
10. Devesa SS, Blot WJ, Fraumeni JF Jr, (1998). Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83: 2049-2053.
11. Di Martino E, Wild CP, Rotimi O, Darnton JS, Ollivier RJ, Hardie LJ, (2006). IGFBP-3 and IGFBP-10 (CYR61) up regulation during the development of Barrett's oesophagus and associated oesophageal adenocarcinoma: potential biomarkers of disease risk. Biomarkers 11: 547-561.
12. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, Helson L, (1990). Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 50: 4929-4930.
13. Donfrancesco A, Deb G, Dominici C, Angioni A, Caniglia M, De Sio L, et al. (1992). Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol 15: 319-322.
14. Donfrancesco A, De Bernardi B, Carli M, Mancini A, Nigro M, De Sio L, et al. (1995). Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group. Eur J Cancer 31A: 612-615.
15. Estrov Z, Tawa A, Wang XH, Dube ID, Sulh H, Cohen A, et al. (1987). In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 69: 757-761.
16. Fang D, Bao Y, Li X, Liu F, Cai K, Gao J, et al. (2010). Effects of iron deprivation on multidrug resistance of leukemic K562 cells. Chemotherapy 56: 9-16.
17. Fukushima T, Kawabata H, Nakamura T, Iwao H, Nakajima A, Miki M, et al. (2011). Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. Anticancer Res 31: 1741-1744.
18. Grünberger B, Raderer M, Schmidinger M, Hejna M, (2007). Palliative chemotherapy for recurrent and metastatic esophageal cancer. Anticancer Res 27: 2705-2714.
19. Haggitt RC, (1994). Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25: 982-993.
20. Hann HW, Stahlhut MW, Blumberg BS, (1988). Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Cancer Res 48: 4168-4170.
21. Hormi-Carver K, Zhang X, Zhang HY, Whitehead RH, Terada LS, Spechler SJ, et al. (2009). Unlike esophageal squamous cells, Barrett's epithelial cells resist apoptosis by activating the nuclear factor-kappaB pathway. Cancer Res 69: 672-677.
22. Ilsley JN, Belinsky GS, Guda K, Zhang Q, Huang X, Blumberg JB, et al. (2004). Dietary iron promotes azoxymethane-induced colon tumors in mice. Nutr Cancer 49: 162-191.
23. Kemp JD, Cardillo T, Stewart BC, Kehrberg E, Weiner G, Hedlund B, et al. (1995). Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. Cancer Res 55: 3817-3824.
24. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
25. Kovacevic Z, Kalinowski DS, Lovejoy DB, Yu Y, Suryo Rahmanto Y, Sharpe PC, et al. (2011). The medicinal chemistry of novel iron chelators for the treatment of cancer. Curr Top Med Chem 11: 483-499.
26. Lagergren J, (2005). Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 54 (Suppl. 1): 1-5.
27. Le NT, Richardson DR, (2002). The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 1603: 31-46.
28. Lescoat G, Chantrel-Groussard K, Pasdeloup N, Nick H, Brissot P, Gaboriau F, (2007). Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism. Cell Prolif 40: 755-767.
29. Lindsey WT, Olin BR, (2007). Deferasirox for transfusion-related iron overload: a clinical review. Clin Ther 29: 2154-2166.
30. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
31. Merlot AM, Kalinowski DS, Richardson DR, (2012). Novel chelators for cancer treatment: where are we now? Antioxid Redox Signal. DOI: 10.1089/ars.2012.4540 [Epub ahead of print].
32. Messa E, Carturan S, Maffè C, Pautasso M, Bracco E, Roetto A, et al. (2010). Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 95: 1308-1316.
33. Muckenthaler MU, Galy B, Hentze MW, (2008). Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr 28: 197-213.
34. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, et al. (2003). Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 361: 1597-1602.
35. Ohyashiki JH, Kobayashi C, Hamamura R, Okabe S, Tauchi T, Ohyashiki K, (2009). The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci 100: 970-977.
36. Pierre F, Tache S, Petit CR, Van der Meer R, Corpet DE, (2003). Meat and cancer: haemoglobin and haemin in a low-calcium diet promote colorectal carcinogenesis at the aberrant crypt stage in rats. Carcinogenesis 24: 1683-1690.
37. Richardson DR, (2002). Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol 42: 267-281.
38. Richardson DR, Tran EH, Ponka P, (1995). The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86: 4295-4306.
39. Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB, et al. (2009). Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta 1790: 702-717.
40. Rockett JC, Larkin K, Darnton SJ, Morris AG, Matthews HR, (1997). Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br J Cancer 75: 258-263.
41. Seril DN, Liao J, Yang CS, Yang GY, (2005). Systemic iron supplementation replenishes iron stores without enhancing colon carcinogenesis in murine models of ulcerative colitis: comparison with iron-enriched diet. Dig Dis Sci 50: 696-707.
42. Song S, Christova T, Perusini S, Alizadeh S, Bao RY, Miller BW, et al. (2011). Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers. Cancer Res 71: 7628-7639.
43. Takashima N, Ishiguro H, Kuwabara Y, Kimura M, Mitui A, Mori Y, et al. (2008). Gene expression profiling of the response of esophageal carcinoma cells to cisplatin. Dis Esophagus 21: 230-235.
44. Tanswell I, Steed H, Butterworth J, Townson G, (2011). Anaemia is of prognostic significance in patients with oesophageal adenocarcinoma. J R Coll Physicians Edinb 41: 206-210.
45. Toyokuni S, (2009). Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci 100: 9-16.
46. Trowbridge IS, Lopez F, (1982). Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc Natl Acad Sci U S A 79: 1175-1179.
47. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M, (2006). Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160: 1-40.
48. Wang JS, Guo M, Montgomery EA, Thompson RE, Cosby H, Hicks L, et al. (2009). DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. Am J Gastroenterol 104: 2153-2160.
49. Ward MH, Cross AJ, Abnet CC, Sinha R, Markin RS, Weisenburger DD, (2012). Heme iron from meat and risk of adenocarcinoma of the esophagus and stomach. Eur J Cancer Prev 2: 134-138.
50. Whitnall M, Howard J, Ponka P, Richardson DR, (2006). A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A 103: 14901-14906.
51. Yen CJ, Izzo JG, Lee DF, Guha S, Wei Y, Wu TT, et al. (2008). Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res 68: 2632-2640.
52. Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR, (2006). Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res 12: 6876-6883.
53. Yuan J, Lovejoy DB, Richardson DR, (2004). Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104: 1450-1458.
54. Zhang H, Xu L, Xiao D, Xie J, Zeng H, Wang Z, et al. (2007). Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion. J Clin Pathol 60: 555-561.